Mild Cognitive Impairment Market

Increasing burden of mild cognitive impairment across the globe fuels market growth

The increasing prevalence of mild cognitive impairment (MCI) globally is serving as a significant catalyst for the expansion of the global MCI treatment market. For instance, in October 2023, the University of Southern California (US) reported that approximately eight million Americans are suffering from mild cognitive impairment. Furthermore, in January 2024, CORDIS revealed that more than 10 million Europeans show MCI. Also, in March 2022, Karolinska Institute stated that more than one fourth of the older population in rural China was affected by MCI. Moreover, one of the major factors contributing to mild cognitive impairment is the growing geriatric population.

As per the Alzheimer’s Association 2022 report, nearly 12% to 18% of people aged 60 or older are living with MCI in America. According to the World Population Prospects 2022, the population over the age of 65 is growing faster than the population under that age. Hence, the increasing MCI cases contributed to the increase in the burden of MCI, boosting the demand for treatment interventions across the globe and thus burgeoning the Mild Cognitive Impairment Market.

Technological advancements in diagnostic tools are significantly influencing the Global Mild Cognitive Impairment Market Industry. Innovations such as neuroimaging techniques and biomarker identification enable healthcare professionals to detect mild cognitive impairment more accurately and earlier than before. These advancements not only enhance diagnostic precision but also facilitate timely interventions, which are crucial for improving patient outcomes. As the market evolves, the integration of artificial intelligence in diagnostic processes may further streamline assessments, potentially increasing the market's value to 3.87 USD Billion by 2035. This trend underscores the importance of technological integration in addressing cognitive health challenges.

The Global Mild Cognitive Impairment Market Industry is also shaped by the development of enhanced support services and care models tailored for individuals with cognitive impairments. These services include specialized care facilities, community-based programs, and telehealth solutions that provide accessible support to patients and their families. The integration of holistic approaches to care, which encompass physical, emotional, and social well-being, is becoming increasingly important. As these services evolve, they are likely to attract more individuals seeking assistance, thereby contributing to the market's growth trajectory. This trend emphasizes the need for comprehensive care solutions in addressing the complexities of mild cognitive impairment.

The Global Mild Cognitive Impairment Market Industry is benefiting from rising awareness and education initiatives aimed at both healthcare professionals and the general public. Campaigns designed to educate individuals about the signs and symptoms of mild cognitive impairment are crucial for early detection and intervention. Increased awareness leads to higher rates of diagnosis and treatment, which in turn drives market growth. Furthermore, educational programs targeting caregivers and families play a vital role in supporting those affected by cognitive impairment. As awareness continues to grow, the market is poised to expand, reflecting a collective effort to address cognitive health challenges.

The Global Mild Cognitive Impairment Market Industry is experiencing growth due to the rising prevalence of cognitive disorders among the aging population. As individuals age, the risk of developing mild cognitive impairment increases, with estimates suggesting that approximately 15 to 20 percent of older adults may experience this condition. This demographic shift is projected to drive the market value to 2.05 USD Billion in 2024, highlighting the urgent need for effective interventions and support systems. The increasing awareness of cognitive health and the importance of early diagnosis further contribute to the demand for services and products within this market.

Investment in research and development is a key driver for the Global Mild Cognitive Impairment Market Industry. Governments and private organizations are increasingly funding studies aimed at understanding the underlying mechanisms of mild cognitive impairment and exploring new therapeutic options. This focus on research is expected to yield innovative treatments and preventive measures, thereby expanding the market. The anticipated compound annual growth rate (CAGR) of 5.93% from 2025 to 2035 reflects the growing recognition of the need for effective solutions in cognitive health. Such investments are likely to enhance the overall landscape of the market, fostering advancements that could benefit millions.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America mild cognitive impairment market accounted for the largest market share of 42.60% in 2022 and is anticipated to reach approximately USD 01.31 billion by 2032 at a 4.97% CAGR during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 6.91% during the forecast period. The outlook for the North America mild cognitive impairment market remains promising, with sustained growth anticipated.

Investments in healthcare infrastructure and a growing awareness of advanced medical solutions are expected to drive market expansion further. Both established players and emerging entrants are poised to capitalize on these opportunities, leveraging technological advancements to meet the rising demand for improved surgical outcomes.

Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MILD COGNITIVE IMPAIRMENT MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe mild cognitive impairment market accounted for the second-largest market share due to technology advancements, increasing healthcare expenditure, and increasing burden of mild cognitive impairment. Furthermore, the Germany mild cognitive impairment market is attributed to hold the largest market share, and the UK mild cognitive impairment market is projected be the fastest growing market in the Europe region.

The Asia-pacific mild cognitive impairment market is expected to be the fastest growing from 2024 to 2032 owing to high patient population, rising number of mild cognitive cases, and favorable regulatory policies. Moreover, key players working in the mild cognitive impairment market are actively expanding into this region, further driving the regional market growth. Moreover, China mild cognitive impairment market accounted to hold the largest market share, and the India mild cognitive impairment market is projected to be the fastest growing market in the Asia-Pacific region.

The Mild Cognitive Impairment Market is distinguished by the presence of numerous regional and local players catering to mild cognitive impairment market products that are evolving at a rapid pace. Furthermore, the increasing burden of mild cognitive impairment across the globe and rising awareness associated with mild cognitive impairment in the healthcare industry is further driving the growth of Mild Cognitive Impairment Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach.

Eisai Co., Ltd. manufactures prescription drugs and medical equipment and primarily sells to sales agents and subsidiaries. They aim to provide services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia.

In January 2023, Eisai Co., Ltd. (Japan) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD.